FLT3 mutations are the most common genetic aberrations found in acute myeloid leukemia
(AML) and associated with poor prognosis. Since the discovery of FLT3 mutations and their …

In the past few years research in the underlying pathogenic mechanisms of acute myeloid
leukaemia (AML) has led to remarkable advances in our understanding of the disease …

Ninety-seven percent of drug-indication pairs that are tested in clinical trials in oncology
never advance to receive US Food and Drug Administration approval. While lack of efficacy …

Diseases of infection, of neurodegeneration (such as Alzheimer's and Parkinson's
diseases), and of malignancy (cancers) have complex and varied causative factors. Modern …

Importance Preventing relapse for adults with acute myeloid leukemia (AML) in first
remission is the most common indication for allogeneic hematopoietic cell transplant. The …

FLT3 mutations are one of the most common findings in acute myeloid leukemia (AML).
FLT3 inhibitors have been in active clinical development. Midostaurin as the first-in-class …

FMS-like tyrosine kinase 3 (FLT3) is a receptor tyrosine kinase that is expressed almost
exclusively in the hematopoietic compartment. Its ligand, FLT3 ligand (FL), induces …

Precision cancer medicine (PCM) is a concept in which oncologists increasingly strive to
tailor the use of targeted therapies in order to match the complexity of the cancer genome …

FLT3 mutations are prevalent in AML patients and confer poor prognosis. Crenolanib, a
potent type I pan-FLT3 inhibitor, is effective against both internal tandem duplications and …

Considerable progress has been made in the past several years in the scientific
understanding of, and available treatments for, acute myeloid leukemia (AML). Achievement …